Moderna and Merck have announced a significant breakthrough in cancer treatment. Their experimental mRNA vaccine has shown promising results in preventing the return and spread of melanoma in high-risk patients.
This development, reported on August 19, 2026, offers new hope for individuals battling this aggressive form of skin cancer, marking a potential advancement in medical science in the United States.